Insights & Innovators: Using Machine Learning to Develop Disease Predictability Models
A Q&A with Chao Li, PhD
Insights & Innovators: A Q&A with Greg Norman and Poorva Nemlekar from Dexcom
Greg Norman, PhD is Director of Health Economics and Outcomes Research at Dexcom where he leads studies to assess real-world evidence of the clinical and health economic impact of continuous glucose monitors for people with diabetes. Poorva Nemlekar, MS is the Lead HEOR Specialist within the Global Access team at Dexcom. Poorva works on multiple[…]
Insights & Innovators: A Q&A with Greg Norman and Katia Hannah from Dexcom
Greg Norman, PhD, is Director of Health Economics and Outcomes Research at Dexcom where he leads the generation of real-world evidence to support the clinical and health economic impact of continuous glucose monitors for people with diabetes. Katia Hannah, PhD, MPH, is the Senior Health Economics and Outcomes Research Specialist within Dexcom’s[…]
Building a Real-World Evidence Center of Excellence: Lessons from the Frontlines
A Q&A with Margaret McDonald, Head of Apex Data Consulting, LLC, following a 17+ year career at Pfizer. Margaret McDonald is an accomplished analytic research scientist, healthcare executive and former hospital laboratory administrator with a Ph.D. in epidemiology, specializing in real-world data and analytics (RWD). She has expertise in global[…]
The Importance of Accounting for Time-Related Bias in Single-Arm Trials with Historical Controls (Part 2)
A Q&A with Samy Suissa, PhD In our previous blog post, we sat down with Dr. Samy Suissa, the co-founder and principal investigator of the Canadian Network for Observational Drug Effect Studies, to discuss the main themes from his recent journal article in Epidemiology. Namely, he argues that while single-arm trials with historical controls are[…]
The Importance of Accounting for Time-Related Bias in Single-Arm Trials with Historical Controls (Part 1)
A Q&A with Samy Suissa, PhD Randomized control trials (RCTs) are typically heralded as the gold standard in clinical trial design. However, regulatory agencies are increasingly recognizing the role of single-arm trials that leverage historical controls, especially within the rare disease space. Yet while these single-arm trials could have[…]
The Use of RWE in ICER Evaluations: What It Means for Life Sciences Companies
Real-world evidence (RWE) has been gaining acceptance at a rapid rate in many areas of the life sciences industry including R&D, epidemiology, outcomes research, and commercial groups. The COVID-19 pandemic and resulting research to find treatments and vaccines has accelerated the growth and adoption of RWE as well. The Institute for Clinical and[…]
Leveraging RWD in Observational Studies: Understanding the Implications of Time-Related Biases
A Q&A with Samy Suissa, PhD Dr. Samy Suissa is a Co-Founder and Principal Investigator of the Canadian Network for Observational Drug Effect Studies (CNODES). He is Director of the Centre for Clinical Epidemiology, Lady Davis Institute for Medical Research at the Jewish General Hospital and Professor, Departments of Epidemiology and Biostatistics[…]
Innovating RWE Organizations: Learning from the Past and Looking to the Future
A Q&A with Christopher Boone, PhD, FACHE, FHIMMS Christopher Boone, PhD, is Vice President, Global Head of Health Economics and Outcomes Research at AbbVie. He is also an adjunct assistant professor of health administration at the New York University's Robert F. Wagner Graduate School of Public Service, an active board member of several health[…]